Bio-Rad Laboratories, Inc.
BIOHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Bio-Rad Laboratories, Inc. (BIO) is listed under Medical Devices. The $8.15B market capitalization puts BIO squarely in mid-cap range for its industry. It operates through two segments, Life Science and Clinical Diagnostics.
Market Cap
$8.15B
Beta
1.08
P/E (TTM)
49.98
P/E (Fwd)
31.31
EPS (TTM)
$6.09
EPS (Fwd)
$9.72
ROE
2.5%
ROA
1.8%
Cash
$1.56B
Total Debt
$1.38B
Free CF
$229.8M
52W Change
23.5%
Annual Financials
Cash vs Debt
Bio-Rad Laboratories, Inc. holds $1.56B in cash against $1.38B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $229.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 2.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.80B (2022) to $2.58B (2025).
Investors considering Bio-Rad Laboratories, Inc. should weigh the typical risks associated with BIO's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bio-Rad Laboratories, Inc. and its sector.